ELEMENTARY

ELEMENTARY offers a proprietary preclinical screening platform built on patient-derived tumor models specifically developed for rare endocrine cancers, a disease area currently underserved by standard drug discovery pipelines. The platform is designed to identify compounds with direct clinical translatability, significantly reducing the gap between preclinical screening and early-phase clinical application. The platform is currently in validation phase on MTC, with a clear development roadmap toward the broader NET space.